RecruitingPHASE2, PHASE3NCT03651206
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Studying Malignant mixed Müllerian tumor of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ARCAGY/ GINECO GROUP
- Intervention
- Niraparib(drug)
- Enrollment
- 138 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2020 – 2027
Study locations (30)
- ICO Paul Papin, Angers, France
- CHRU Jean Minjoz, Besançon, France
- Centre Régional de Lutte contre le cancer - Institut Bergonié, Bordeaux, France
- CHU de BREST - Hôpital Cavale Blanche, Brest, France
- Centre François Baclesse, Caen, France
- Centre Jean Perrin, Clermont-Ferrand, France
- Centre Georges François Leclerc, Dijon, France
- Centre Oscar Lambret, Lille, France
- CHU de Limoges - Hôpital Dupuytren, Limoges, France
- Centre Léon Bérard, Lyon, France
- Institut Paoli Calmettes, Marseille, France
- Hôpital Privé du Confluent S.A.S., Nantes, France
- Centre Hospitalier Universitaire de Nîmes, Institut de Cancérologie du GARD, Nîmes, France
- Groupe Hospitalier des Diaconesses Croix Saint-Simon, Paris, France
- Institut Curie, Paris, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Tesaro, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03651206 on ClinicalTrials.govOther trials for Malignant mixed Müllerian tumor of the ovary
Additional recruiting or active studies for the same condition.
See all trials for Malignant mixed Müllerian tumor of the ovary →